Alzheimer's

Medicare finalizes decision to limit coverage of controversial Alzheimer’s drug to those in clinical trial

The Biden administration on Thursday finalized a decision to significantly limit Medicare coverage of a controversial new Alzheimer’s drug amid a fierce debate over its effectiveness.

The Centers for Medicare and Medicaid Services said that it would limit coverage of the drug, known as Aduhelm, to people who are participating in a clinical trial, which can help scientists further study the drug.